Physician profile
Samreen Choudhry
NPI 1447531017
$2,480.55
in general payments reported to CMS, 2019-2025
21 companies · $529 in 2025
The $529 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $224 · 2021: $110 · 2022: $222 · 2023: $496 · 2024: $642 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,667.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $387.45 | 2019-2025 | Skyrizi |
| Genzyme Corporation | $385.19 | 2021-2025 | |
| Lilly USA, LLC | $267.09 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $223.87 | 2023-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $158.48 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $128.04 | 2020-2024 | Dupixent |
| Leo Pharma INC. | $111.31 | 2020-2025 | Anzupgo |
| Galderma Laboratories, L.P. | $104.71 | 2019-2022 | |
| Pfizer INC. | $103.80 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.90 | 2022-2025 | Jublia, Arazlo, Cabtreo |
| Incyte Corporation | $80.74 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $72.60 | 2019-2024 | |
| Vyne Pharmaceuticals INC. | $62.60 | 2020-2021 | |
| Janssen Biotech, INC. | $52.20 | 2025 | Tremfya |
| Allergan, INC. | $50.50 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $41.92 | 2020 | |
| Almirall LLC | $40.21 | 2019-2025 | Klisyri |
| Journey Medical Corporation | $37.30 | 2023 | |
| Merz North America, INC. | $33.15 | 2019 | |
| Revance Therapeutics, INC. | $27.66 | 2024 | Daxxify |
| Mayne Pharma Commercial LLC | $15.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samreen Choudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.